A Combined Multi-omics and Exploratory Bioinformatics Approach to Explore Disease Mechanisms in Complex Neuropsychiatric Disorders

The Bahn laboratory is conducting an extensive research programme to define the molecular basis of schizophrenia and bipolar affective disorder. The internationally recognised scientific team is supported by 'state of the art' laboratory facilities at the Institute of Biotechnology, Cambridge. A research unit has been established within the Institute, the Cambridge Centre for Neuropsychiatric Research (CCNR), under the direction of Dr Sabine Bahn. The centre aims to conduct and coordinate fundamental empirical research into major neuropsychiatric diseases, focusing on biomarkers and novel target discovery and translating the finding from the bench to the bed. The Bahn group has received the second largest centre grant awarded by the Stanley Medical Research Institute (SMRI), has attracted support and interest from prominent pharmaceutical companies, and found promising results to justify expanding research.

Lab Album